A new drug based on decades of research at the University of Cambridge has today been approved by the National Institute for Health and Care Excellence (NICE) for use in people with relapsing-remitting multiple sclerosis. Clinical trials have shown that Alemtuzumab, marketed under the name Lemtrada, reduces disease activity, limits the accumulation of further disability over time and may even allow some existing damage to recover.
Scientists at the University of Cambridge have identified a key chemical that can repair the damage to cells which causes a rare but devastating disease involving accelerated ageing. As well as offering a promising new way of treating the condition, known as Hutchinson-Gilford Progeria Syndrome (HGPS), the discovery could help in the development of drugs against cancer and other genetic diseases and might also suggest ways to alleviate diseases that we associate with normal ageing.
The structure of sodium channels – which play an essential role in the functioning of heart and nerve cells – are different than previously believed. Researchers hope their discovery will lead to improvements in drugs that act on the sodium channel to treat a range of cardiac and pain conditions.
Out of mind, out of sight: suppressing unwanted memories reduces their unconscious influence on behaviour18 Mar 2014
New research shows that, contrary to what was previously assumed, suppressing unwanted memories reduces their influence on behaviour, and sheds light on how this process happens in the brain.
A University of Cambridge cancer research laboratory which uses imaging technologies to measure key biologic changes within growing tumours has announced a three-year oncology research collaboration with Medimmune.
Two teams of University of Cambridge students have won a prestigious international competition to commercialise innovative breast cancer research.